Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

ViiV Healthcare

Status: Completed

Conditions: CCR5-tropic HIV-1 Infection

Treatments: Drug: CELSENTRI® Tablets

Study type: Observational

Funder types: Industry

Identifiers

NCT00864474

A4001093

Details and patient eligibility

About

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Full description

All the patients whom an investigator prescribes the first CELSENTRI® Tablets should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Enrollment: 68 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients need to be administered CELSENTRI® Tablets in order to be enrolled in the surveillance.

Exclusion criteria

Patients not administered CELSENTRI® Tablets.

Trial design

68 participants in 1 patient group

Maraviroc Tablets

Description:

Patients administered.

Treatment:

Drug: CELSENTRI® Tablets